The Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes has reported another half (to May 2016) of strong scientific and commercial progress. Operational prudence has kept losses in check (£0.6m from £0.5m) and the balance sheet remains robust after continued investor support with period end cash of £3.55m.
30 Aug 2016
Progress on all fronts
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Progress on all fronts
OptiBiotix Health PLC (OPTI:LON) | 18.0 0 0.0% | Mkt Cap: 17.6m
- Published:
30 Aug 2016 -
Author:
Derren Nathan -
Pages:
7
The Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes has reported another half (to May 2016) of strong scientific and commercial progress. Operational prudence has kept losses in check (£0.6m from £0.5m) and the balance sheet remains robust after continued investor support with period end cash of £3.55m.